ストックスクリーナーアプリを入手
2.28
6.56%
-0.16
前日終値:
$2.44
開ける：
$2.43
24時間の取引高:
138.26K
Relative Volume:
0.29
時価総額：
$16.11M
収益：
-
当期純損益:
$-30.33M
株価収益率:
-0.0813
EPS:
-28.0369
ネットキャッシュフロー:
$-24.28M
1週間 パフォーマンス:
-13.64%
1か月 パフォーマンス:
-8.80%
6か月 パフォーマンス:
-42.71%
1年 パフォーマンス:
-82.92%
1日の値動き範囲:
$2.25
$2.43
1週間の範囲:
$2.19
$2.6499
52週間の値動き範囲:
$1.79
$24.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.28 | 16.11M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - ad-hoc-news.de
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment - marketscreener.com
Moleculin CEO discusses preliminary results from leukemia trial By Investing.com - Investing.com Australia
Moleculin CEO discusses preliminary results from leukemia trial - Investing.com
Moleculin reports positive early results from P... - Pluang
Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative
Moleculin says early MIRACLE trial data support Annamycin in leukemia - Stock Titan
Moleculin Biotech | 8-K: Current report - Moomoo
MBRXMoleculin Biotech Inc Dividends - Finviz
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
Why is Moleculin stock falling today? - MSN
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable
Moleculin Biotech, Inc. Financial Disclosures & Filings - TradingView
Why is Moleculin Stock Falling Today? - Benzinga
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech (MBRX) Reports Positive Efficacy Results in Ph - GuruFocus
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget
Moleculin reports positive interim data from AML trial - Investing.com
Moleculin Biotech Updates Investors With New Presentation - TipRanks
Moleculin Biotech Reports Promising Annamycin AML Trial Data - TipRanks
Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart
Moleculin reports positive interim data from AML trial By Investing.com - Investing.com India
Form 8-K Moleculin Biotech, Inc. For: Jun 30 - StreetInsider
Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised - Stock Titan
Moleculin Reports Positive Phase 2/3 MIRACLE Interim - GlobeNewswire
MBRX Forecast — Price Target — Prediction for 2027 - TradingView
Moleculin Biotech, Inc. Actuals & Estimates (MUN:MOL0) - TradingView
Moleculin Biotech, Inc. Actuals & Estimates (LSE:0K2H) - TradingView
0K2H Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Moleculin Biotech Inc For: 24 June By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake - Stock Titan
Moleculin Biotech (MBRX) CSO exercises RSUs with tax withholding, increases common stock stake - Stock Titan
Moleculin Biotech | 4: Statement of changes in beneficial ownership of securities-Officer PICKER DONALD H - Moomoo
MBRX Stock Whipsaws As Traders Focus On Cash Runway - StocksToTrade
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
MBRX Stock Draws Trader Focus As Volatility Spikes - timothysykes.com
$Moleculin Biotech (MBRX.US)$ - Moomoo
Trending Stocks Today | Moleculin Biotech Shoots up 106.41% Pre-Market - Moomoo
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):